
Tuesday, October 22, 2024 4:19:50 AM
Recent ATNM News
- Shareholders that lost money on Actinium Pharmaceuticals, Inc.(ATNM) should contact The Gross Law Firm about pending Class Action - ATNM • PR Newswire (US) • 04/24/2025 09:45:00 AM
- Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) - May 27, 2025 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/21/2025 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Pharmaceuticals, Inc. Lawsuit - ATNM • PR Newswire (US) • 04/17/2025 09:45:00 AM
- Kuehn Law Encourages Investors of Actinium Pharmaceuticals, Inc. to Contact Law Firm • PR Newswire (US) • 04/16/2025 12:57:00 AM
- With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz • PR Newswire (US) • 04/14/2025 02:15:00 PM
- With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz • PR Newswire (Canada) • 04/14/2025 02:10:00 PM
- With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz • PR Newswire (US) • 04/14/2025 02:10:00 PM
- The Gross Law Firm Notifies Actinium Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ATNM • PR Newswire (US) • 04/10/2025 09:45:00 AM
- Shareholders that lost money on Actinium Pharmaceuticals, Inc.(ATNM) should contact The Gross Law Firm about pending Class Action - ATNM • PR Newswire (US) • 04/07/2025 09:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2025 10:22:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2025 10:22:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2025 10:21:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2025 10:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2025 10:20:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2025 10:20:36 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:00:42 PM
- Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225 • PR Newswire (US) • 03/27/2025 12:45:00 PM
- Actinium Pharmaceuticals Provides Business Update After Presentation at Trump Mar-A-Lago Club Announcing Novel Non-PSMA Prostate Cancer Radiotherapy ATNM-400 and Outlining Revitalized Clinical Pipeline with 2025 Corporate Objectives • PR Newswire (US) • 03/27/2025 11:30:00 AM
- Actinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club Today • PR Newswire (US) • 03/26/2025 12:45:00 PM
- Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program • PR Newswire (US) • 03/25/2025 10:00:00 AM
- Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities • PR Newswire (US) • 03/24/2025 08:15:00 PM
- Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy • PR Newswire (US) • 03/20/2025 12:00:00 PM
- Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical D • PR Newswire (US) • 03/19/2025 12:30:00 PM
- Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO® • PR Newswire (US) • 03/18/2025 12:00:00 PM
- Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia • PR Newswire (US) • 03/17/2025 12:50:00 PM
FEATURED Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement • Apr 25, 2025 8:33 AM
UAV Corp. Successfully Completes Inflation Test of DART SA-70 Airship, Paving Way for Flight Readiness • UMAV • Apr 24, 2025 8:30 AM
InnerScope Hearing Technologies (OTC: INND) Announces the Grand Opening of OTCHealthMart.com • INND • Apr 24, 2025 8:00 AM
Opus Holdings Unveils Powerhouse Leadership Team to Drive Aggressive Growth and Transform Market Trajectory • CATV • Apr 22, 2025 8:30 AM
Glidelogic Corp. (OTCQB: GDLG) Highlights Independent SOTA Evaluation of ResearchMind Platform • GDLG • Apr 22, 2025 6:54 AM
UAV Corp to Launch Inflation Test of SA-70 Airship This Week-A Gateway to High-Value Government and Defense Contracts • UMAV • Apr 21, 2025 1:30 PM